Nanopath Revenue and Competitors
Estimated Revenue & Valuation
- Nanopath's estimated annual revenue is currently $2.2M per year.
- Nanopath's estimated revenue per employee is $77,500
- Nanopath's total funding is $11M.
Employee Data
- Nanopath has 28 Employees.
- Nanopath grew their employee count by 27% last year.
Nanopath's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Co-Founder & Co-CEO | Reveal Email/Phone |
3 | VP Assay Development | Reveal Email/Phone |
4 | Associate Director Engineering | Reveal Email/Phone |
5 | Senior Research Associate | Reveal Email/Phone |
6 | Research Engineer | Reveal Email/Phone |
7 | Research Engineer | Reveal Email/Phone |
8 | Senior Scientist | Reveal Email/Phone |
9 | Computational Scientist II | Reveal Email/Phone |
10 | Assay Development & Commercial Strategy Associate | Reveal Email/Phone |
Nanopath Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Nanopath?
Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. We aim to improve the health of women by providing granular and clinically actionable information within a single office visit.
keywords:N/A$11M
Total Funding
28
Number of Employees
$2.2M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4M | 28 | -70% | N/A |
#2 | $2.8M | 28 | N/A | N/A |
#3 | $2.2M | 28 | -35% | $108.9M |
#4 | $3.5M | 28 | 0% | N/A |
#5 | $3.5M | 28 | -3% | N/A |